GDC-0425 RG-7602|cas:1200129-48-1|西域试剂

GDC-0425 RG-7602,99.48%

产品编号：Bellancom-19926| CAS NO：1200129-48-1| 分子式：C₁₈H₁₉N₅O| 分子量：321.38

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	价格	库存与货期
Bellancom-19926	￥700.00	杭州北京（现货）
Bellancom-19926	￥1100.00	杭州北京（现货）
Bellancom-19926	￥2200.00	杭州北京（现货）
Bellancom-19926	￥3800.00	杭州北京（现货）
Bellancom-19926	￥6000.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

GDC-0425 RG-7602

产品介绍

GDC-0425 (RG-7602) 是一种有效的、具有口服活性的、高选择性的 ChK1 抑制剂。GDC-0425 可用于多种恶性肿瘤的研究。

生物活性

GDC-0425 (RG-7602) is an orally available, highly selective small molecule ChK1 inhibitor. GDC-0425 can be used for the research of various malignancies.

体外研究

MEK inhibition either by pharmacologic inhibitors or RNAi-mediated gene silencing significantly protected cells from reduced viability upon GDC-0425 treatment.
GDC-0425 (3 μM; 24 hours) treatment results the hyperphosphorylation of Chk1.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line:	Chk1-positive breast cancer cell lines
Concentration:	0.001, 0.01, 0.1, 1, 10 mM
Incubation Time:	72 hours
Result:	Reduced cell proliferation.

Cell Viability Assay

Cell Line:	U-2 OS cells
Concentration:	3 μM
Incubation Time:	24 hours
Result:	Led to hyperphosphorylation of Chk1.

体内研究
(In Vivo)

GDC-0425 exhibits partial suppression of tumor growth. The Gemcitabine/GDC-0425 combination results in significant tumor regression in all tested models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCr nude mice bearing xenografts of both osteosarcoma and triple-negative breast cancer models (143B PML BK TK, HCC1806, and HCC70 cell lines)
Dosage:	For the 4-arm study, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination for 15 days. For 6-arm studies of HCC1806 and HCC70 models, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 50 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination.
Administration:	Orally administrated at 24, 48, and 72 hours after gemcitabine administration by intraperitoneal injection.
Result:	Exhibited partial suppression of tumor growth upon treatment with either Gemcitabine or GDC-0425 alone. Notably, the Gemcitabine/GDC-0425 combination resulted in significant tumor regression in all tested models.

体内研究

GDC-0425 exhibits partial suppression of tumor growth. The Gemcitabine/GDC-0425 combination results in significant tumor regression in all tested models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCr nude mice bearing xenografts of both osteosarcoma and triple-negative breast cancer models (143B PML BK TK, HCC1806, and HCC70 cell lines)
Dosage:	For the 4-arm study, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination for 15 days. For 6-arm studies of HCC1806 and HCC70 models, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 50 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination.
Administration:	Orally administrated at 24, 48, and 72 hours after gemcitabine administration by intraperitoneal injection.
Result:	Exhibited partial suppression of tumor growth upon treatment with either Gemcitabine or GDC-0425 alone. Notably, the Gemcitabine/GDC-0425 combination resulted in significant tumor regression in all tested models.

体内研究

GDC-0425 exhibits partial suppression of tumor growth. The Gemcitabine/GDC-0425 combination results in significant tumor regression in all tested models.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCr nude mice bearing xenografts of both osteosarcoma and triple-negative breast cancer models (143B PML BK TK, HCC1806, and HCC70 cell lines)
Dosage:	For the 4-arm study, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination for 15 days. For 6-arm studies of HCC1806 and HCC70 models, mice were treated with vehicle, Gemcitabine 120 mg/kg, GDC-0425 50 mg/kg, GDC-0425 75 mg/kg alone, or Gemcitabine and GDC-0425 combination.
Administration:	Orally administrated at 24, 48, and 72 hours after gemcitabine administration by intraperitoneal injection.
Result:	Exhibited partial suppression of tumor growth upon treatment with either Gemcitabine or GDC-0425 alone. Notably, the Gemcitabine/GDC-0425 combination resulted in significant tumor regression in all tested models.

性状

Solid

溶解性数据

In Vitro:

H₂O : 25 mg/mL (77.79 mM; ultrasonic and adjust pH to 3 with HCl)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	3.1116 mL	15.5579 mL	31.1158 mL
5 mM	0.6223 mL	3.1116 mL	6.2232 mL
10 mM	0.3112 mL	1.5558 mL	3.1116 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式